Market Size of Controlled Release Drug Delivery Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 5.60 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Controlled Release Drug Delivery Market Analysis
The Controlled Release Drug Delivery Market is expected to register a CAGR of 5.60% during the forecast period.
The rising prevalence of chronic diseases is anticipated to boost the demand for controlled-release drug delivery technology as it maximizes the efficacy of the therapeutic and minimizes the side effects, which adds to the market's growth.
The rising incidence of chronic diseases is expected to boost the demand for controlled-release drug delivery technology. This technology offers several advantages, including improved patient compliance, reduced dosing frequency, and enhanced therapeutic efficacy. Chronic diseases such as diabetes, cardiovascular diseases, and cancer continue to increase, and the need for advanced drug delivery systems becomes more critical. Consequently, the controlled-release drug delivery technology market is anticipated to grow during the forecast period. For instance, according to the data updated by the Spanish Network of Cancer Registries (REDECAN) in January 2023, an estimated 279,260 new cases of cancer were expected to occur in Spain by the end of 2023, out of which 42,721 new cases of colorectal cancer, 31,282 cases of lung cancer, and 21,694 cases of urinary bladder cancer were expected to occur in Spain in 2023. Thus, the high burden of chronic diseases that require control release formulation to the target cell is anticipated to boost the market's growth during the forecast period.
Additionally, according to June 2024 statistics published by the Australian Institutes of Health and Welfare, there were 53,000 hospitalizations with a principal diagnosis of COPD for people aged 45 and above (500 hospitalizations per 100,000 population) in 2022. Additionally, according to the December 2023 article published by Jama Network, by 2050, the global prevalence of COPD is forecasted to reach nearly 600 million cases, indicating a 23% increase from the 2020 figures. The high burden of COPD worldwide boosts the demand for controlled-release drugs that can be used in various types of inhalers, which are projected to augment the market's growth during the forecast period.
Furthermore, the strategic initiatives by market players for innovation and launches in existing products also contribute significantly to market growth. For instance, in February 2022, AstraZeneca launched the Ambition Zero Carbon Program in partnership with Honeywell to develop next-generation respiratory inhalers. Under the partnership, the companies will eliminate the propellent that was earlier used in metered dose inhalers for patients with asthma and COPD. Therefore, the partnership will boost the development of advanced metered dose inhalers, which is further projected to accelerate the market's growth during the forecast period.
Therefore, factors such as the rising prevalence of chronic disease and increasing strategic initiatives by market players are expected to drive the market's growth during the forecast period. However, the higher cost compared to the conventional method is expected to restrain the market's growth during the forecast period.
Controlled Release Drug Delivery Industry Segmentation
Controlled-release drug delivery is the dosage form that delivers a drug or medication in a predetermined manner. This drug delivery system provides continuous drug or medication delivery in predictable kinetics for the predetermined time in the whole course of gastrointestinal transit.
The controlled release drug delivery market is segmented by technology, application, and geography. By technology, the market is segmented into microencapsulation, transdermal, targeted delivery, and other technologies. By application, the market is segmented into metered dose inhalers, injectables, transdermal, ocular patches, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends of 17 countries across major regions globally.
The report offers values (in USD) for the above segments.
| By Technology | |
| Micro Encapsulation | |
| Transdermal | |
| Targeted Delivery | |
| Other Technologies |
| By Application | |
| Metered Dose Inhalers | |
| Injectable | |
| Transdermal and Ocular Patches | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Controlled Release Drug Delivery Market Size Summary
The controlled-release drug delivery market is experiencing a resurgence as it moves past the disruptions caused by the COVID-19 pandemic, which had initially diverted focus towards vaccine development and imposed manufacturing restrictions. The market is now benefiting from the increasing demand for controlled-release technologies in research and development, particularly in the context of chronic disease management. The rising prevalence of conditions such as cancer and chronic obstructive pulmonary disease (COPD) is driving the need for innovative drug delivery solutions that enhance therapeutic efficacy while minimizing side effects. Strategic initiatives by key market players, including partnerships and product launches, are further propelling market growth. These efforts are aimed at developing advanced drug delivery systems, such as transdermal and inhaler technologies, which are expected to expand the market's reach and application.
The targeted drug delivery segment is poised for significant growth due to its ability to provide prolonged therapeutic effects and its increasing demand among geriatric and pediatric populations. Innovations in this area, such as the development of antibody-drug conjugates, are expected to dominate the market. North America is anticipated to hold a substantial market share, driven by the high incidence of chronic diseases and proactive product launches. The region's market growth is supported by collaborations and technological advancements in transdermal delivery systems. The competitive landscape is characterized by the presence of major players like Adare Pharma Solutions and Merck & Co., Inc., who are actively engaging in research and development to meet the evolving demands of the market.
Controlled Release Drug Delivery Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rise in Incidence of Chronic Diseases
-
1.2.2 Growing Geriatric and Pediatric Population
-
-
1.3 Market Restraints
-
1.3.1 Higher Cost Compared to the Conventional Method
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Technology
-
2.1.1 Micro Encapsulation
-
2.1.2 Transdermal
-
2.1.3 Targeted Delivery
-
2.1.4 Other Technologies
-
-
2.2 By Application
-
2.2.1 Metered Dose Inhalers
-
2.2.2 Injectable
-
2.2.3 Transdermal and Ocular Patches
-
2.2.4 Other Applications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Controlled Release Drug Delivery Market Size FAQs
What is the current Controlled Release Drug Delivery Market size?
The Controlled Release Drug Delivery Market is projected to register a CAGR of 5.60% during the forecast period (2024-2029)
Who are the key players in Controlled Release Drug Delivery Market?
Adare Pharma Solutions, Merck KGaA, Johnson and Johnson, Lonza Group AG (Capsugel) and Colorcon are the major companies operating in the Controlled Release Drug Delivery Market.
